Skip to main content

Table 3 Multivariate analyses for overall survival and scoring system

From: Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Factors independently prognostic of shorter overall survivalHR95%CIp value
Training patient set (n = 903)
 Non-matched therapy1.201.041.380.01
 Performance status > 12.521.943.28< 0.001
 Liver metastases1.521.311.77< 0.001
 LDH > ULN1.661.421.93< 0.001
 PI3K/AKT/mTOR pathway alterations1.181.011.370.03
Validation patient set (n = 404)
 Non-matched therapy1.591.291.96< 0.001
 Performance status > 12.211.533.20< 0.001
 Liver metastases1.351.071.690.01
 LDH > ULN1.701.362.12< 0.001
 PI3K/AKT/mTOR pathway alterations1.431.141.800.002
All patients (N = 1307)
 Non-matched therapy1.321.171.48< 0.001
 Performance status > 12.381.932.95< 0.001
 Liver metastases1.441.281.63< 0.001
 LDH > ULN1.661.461.88< 0.001
 PI3K/AKT/mTOR pathway alterations1.251.101.42< 0.001
Scoring system for survival model    
FactorsHRScore  
Matched therapy    
 Yes1.000  
 No1.321  
Performance status    
 0–11.000  
 2–32.382  
Liver metastases    
 No1.000  
 Yes1.441  
LDH > ULN    
 No1.000  
 Yes1.661  
PI3K/AKT/mTOR pathway alterations    
 No1.000  
 Yes1.251  
  1. Abbreviations: CI confidence interval, HR hazard ratio, LDH lactate dehydrogenase, ULN upper limit of normal